Can-Fite BioPharma Ltd.
CANF | TA
Overview
Corporate Details
- ISIN(s):
- IL0010944739 (+2 more)
- LEI:
- 549300ZLRH6GSBOHFZ59
- Country:
- Israel
- Address:
- PO BOX 7537, 4917000 PETACH-TIKVA
- Website:
- https://www.canfite.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Can-Fite BioPharma Ltd. develops advanced therapies for cancer and inflammatory diseases.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-30 16:00 |
Takeover Announcement Report
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 144.2 KB | |
| 2025-07-30 16:00 |
Regulatory News Service
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% …
|
English | 36.8 KB | |
| 2025-07-29 19:10 |
Prospectus
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 455.7 KB | |
| 2025-07-29 19:10 |
Prospectus
Prospectus Filed pursuant to Rule 424(b)(4)
|
English | 36.7 KB | |
| 2025-07-29 19:07 |
Regulatory News Service
6-K: Report of foreign issuer
|
English | 654.1 KB | |
| 2025-07-29 19:07 |
Regulatory News Service
6-K: Report of foreign issuer
|
English | 36.7 KB | |
| 2025-07-29 01:15 |
Regulatory News Service
Other Report or Announcement
|
English | 160.7 KB | |
| 2025-07-29 01:15 |
Regulatory News Service
Other Report or Announcement
|
English | 36.8 KB | |
| 2025-07-28 16:00 |
Takeover Announcement Report
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment…
|
English | 146.0 KB | |
| 2025-07-28 16:00 |
Regulatory News Service
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment…
|
English | 36.7 KB | |
| 2025-07-26 01:00 |
Registration Form
Other Report or Announcement
|
English | 2.5 MB | |
| 2025-07-26 01:00 |
Regulatory News Service
Other Report or Announcement
|
English | 36.7 KB | |
| 2025-07-24 01:15 |
Registration Form
Other Report or Announcement
|
English | 1.8 MB | |
| 2025-07-24 01:15 |
Regulatory News Service
Other Report or Announcement
|
English | 36.6 KB | |
| 2025-07-01 01:14 |
Regulatory News Service
Other Report or Announcement
|
English | 102.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |